Andy Lim

At the cutting edge of stroke research right here in France #ESOC2022! Here are nine things I learnt from nine trials today! #NeuroTwitter

¡Hola! Looking forward to learning about the latest advances in stroke research. See you soon in Barcelona! #WSC2025

#OpenAccess doi.org/10.1111/1742-6…

Emergency department presentations appear to be increasing in acuity in the state of Victoria, Australia. This rising urgency should prompt the health system to anticipate and prepare accordingly. @EMAJournal @VicGovDH onlinelibrary.wiley.com/doi/full/10.11…

Victorian roads are becoming deadlier despite an overall reduction in road injury burden. link.springer.com/10.1007/s10389…

The contribution of clinical assistants to ED flow and length of stay #OpenAccess doi.org/10.1111/1742-6… @ALim0211 @WileyHealth @acemonline

I've run the simulations and I believe we've discovered something interesting. Aspirin and #ticagrelor appears to be superior to aspirin and #clopidogrel for minor #stroke when clopidogrel resistance has not been excluded. doi.org/10.1001/jamane… @ClayJohnstonMD @GNtem1

@FrontNeurol Thank you, @FrontNeurol, for sharing 🙏! @SCSMonash @MonashUni @MonashHealth

New Research: Rapid outpatient transient ischemic attack clinic and stroke service activity during the SARS-CoV-2 pandemic: a multicenter time series analysis: Background and aim Rapid outpatient evaluation and treatment of TIA in structured… frontiersin.org/articles/10.33… #Neurology

@VivliCenter @MonashUni Thank you for sharing 🙏! @SCSMonash @MonashUni @MonashHealth

Congratulations to Dr. Andy Lim on your public disclosure, “Ninety‐Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta‐Analysis of Trials and Observational Studies.” We’re proud to facilitate your access to data #ClinicalResearch doi.org/10.1161/JAHA.1… @MonashUni

@EMAJournal @WileyHealth @acemonline Thank you for sharing 🙏! @SCSMonash @MonashUni @MonashHealth

The initial and the enduring impact of government lockdown and the pandemic on road injuries doi.org/10.1111/1742-6… #OpenAccess @ALim0211 @WileyHealth @acemonline

@ZHeart11768530 Thank you, @ZHeart11768530, for sharing 🙏! @SCSMonash @MonashUni @MonashHealth @GNtem1

🔴 Comparison of Dual Antiplatelet Therapies for Minor, Nondisabling, Acute Ischemic Stroke: jamanetwork.com/journals/jaman… #medtwitter #foamed #cardiology #CardioEd #CardioTwitter #Cardiogen #CVD #medtwitter #internalmedicine #hospitalist #meded #Medtwitter #Review #MedEd

@ZHeart11768530 Thank you, @ZHeart11768530, for sharing 🙏! @SCSMonash @MonashUni @MonashHealth @GNtem1

✅DAPT w/ aspirin & ticagrelor has higher probability of being the superior Rx among pts w/ minor stroke w/n presence of CYP2C19 loss-of-function alleles has not been excluded. ✅For pts with TIA, superiority of aspirin & ticagrelor vs aspirin & clopidogrel was not demonstrated

@AshuPJadhav Thank you, @AshuPJadhav, for sharing 🙏! @SCSMonash @MonashUni @MonashHealth @GNtem1

Comparison of Dual Antiplatelet Therapies for Nondisabling Acute Ischemic Stroke jamanetwork.com/journals/jaman…

Prof Shelagh Coutts announcing the results of the TEMPO-2 trial: no benefit and possibly harm in non-disabling minor stroke patients with intracranial occlusion treated with intravenous tenecteplase. #ESOC2024

@JAMANetworkOpen @GNtem1 Just announced in Basel, Switzerland! Thank you for listening to my talk! #ESOC2024

Bayesian analysis suggests that DAPT with aspirin + ticagrelor has higher probability of being the superior treatment among patients with minor stroke when presence of CYP2C19 loss-of-function alleles has not been excluded. ja.ma/4asM1Ke @ALim0211 @GNtem1

Just announced in Basel, Switzerland! Thank you for listening to my talk! #ESOC2024

Prof Xiong captivating the audience with TRACE III - tenecteplase reduced disability for Chinese patients with LVO 4.5-24h after onset with no safety concerns. #ESOC2024